Injuries prompt recall of Medtronic insulin sets:
This article was originally published in Clinica
Executive Summary
Medtronic is recalling its Quick-set Plus insulin infusion sets for diabetics in the US after a number of serious injuries and hospitalisations. Bending of the cannula and accidental disconnection at the insertion site causing interruption to the flow of insulin have been reported. The recall has been defined as class I by the FDA, meaning there is "a reasonable probability that the use of the product will cause serious adverse health consequences or death". In March, the company gave customers a tips guide for using the device, and offered replacement sets on request, following increased number of complaints. Medtronic has stopped selling Quick-set Plus sets.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.